Aadi Bioscience, INC 8-K filings

Whitehawk Therapeutics announced Q2 2026 results, highlighting continued enrollment in Phase 1 trials for HWK-007 and HWK-016, with HWK-206 initiation on track for Q3 2026, and an extended cash runway into 2H 2028.

Whitehawk Therapeutics shareholders approved the election of three directors and ratified the appointment of BDO USA, P.C. as auditor.

Whitehawk Therapeutics has secured an option agreement with Hangzhou DAC to access the CPT113 linker-payload for up to five new antibody drug conjugate programs.

Whitehawk Therapeutics announced a $87.5 million private placement equity financing to advance its oncology therapeutics pipeline.

Whitehawk Therapeutics reported Q1 2026 financial results, highlighting ongoing Phase 1 trials and a strong cash position extending into 2028.

Whitehawk Therapeutics announced its full-year 2025 financial results, highlighting active Phase 1 trials for two ADC programs and a strong cash position expected to fund operations into 2028.

Whitehawk Therapeutics reported a significant increase in cash reserves to $162.6 million and confirmed plans for two IND filings by year-end 2025, despite an increased net loss for the quarter.

Whitehawk Therapeutics announced a wider net loss for Q2 2025 but significantly boosted its cash reserves, extending its operational runway into 2028 while advancing its oncology pipeline.

Whitehawk Therapeutics, Inc. announced the successful passage of all proposals at its annual meeting, including the election of three Class II directors, advisory approval of executive compensation, and ratification of its independent auditor, alongside a reduction in board size.

Whitehawk Therapeutics announces Q1 2025 financial results, including net income of $73.0 million driven by the sale of Aadi Sub, and highlights progress in advancing its ADC portfolio.

Whitehawk Therapeutics finalizes the sale of its Aadi Subsidiary to KAKEN INVESTMENTS for $102.4 million and releases pro forma financial statements reflecting the transaction.

Whitehawk Therapeutics finalizes the sale of its Aadi Subsidiary to KAKEN INVESTMENTS INC. for $102.4 million in cash.

Aadi Bioscience rebrands as Whitehawk Therapeutics, shifting focus to antibody drug conjugates (ADCs) and anticipating operational funding into 2028 following strategic transactions.

Aadi Bioscience secures $100 million in a private placement to advance its oncology therapeutics and extend its operational runway into 2028.

Aadi Bioscience has announced a series of strategic moves, including in-licensing a novel ADC portfolio, selling FYARRO for $100 million, and securing a $100 million PIPE financing.

Aadi Bioscience announced a 21% year-over-year increase in FYARRO sales for Q3 2024, alongside updates on clinical trials and a strategic review.

Aadi Bioscience has successfully defended against claims of breach of contract in an arbitration case with EOC Pharma, resulting in no monetary damages.

Aadi Bioscience has approved retention bonuses for its CEO and CFO, contingent on their continued employment through March 31, 2025, or a change of control.

AADI Bioscience reports the departure of its Chief Medical Officer and Executive Chairman, both effective October 1, 2024, with severance and consulting arrangements in place for the departing executives.

Aadi Bioscience is halting its PRECISION1 trial due to efficacy concerns, reducing its workforce by 32% and R&D staff by 80%, and pausing enrollment in other trials to extend its cash runway into the second half of 2026.

Aadi Bioscience announced a 15% quarter-over-quarter sales growth for FYARRO, reaching $6.2 million in Q2 2024, and provided an update on their clinical trials.

Aadi Bioscience held its annual meeting on June 11, 2024, where stockholders elected two Class I directors, approved executive compensation on an advisory basis, and ratified the appointment of BDO USA LLP as the company's auditor for the fiscal year ending December 31, 2024.

Aadi Bioscience announced its Q1 2024 financial results, including FYARRO sales of $5.4 million, and provided an update on its clinical trial progress.

Aadi Bioscience has extended its supply agreement with Fresenius Kabi for FYARRO, modifying terms related to pricing, forecasting, and minimum purchase obligations.

Aadi Bioscience announced a 60% year-over-year increase in FY2023 revenue, driven by FYARRO sales, and provided updates on its clinical trial programs.